The announcement is scheduled for 1 p.m. ET at the White House. AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among major drugmakers expected to announce deals to cut ‌prices on some ‌medicines, according to sources familiar with the matter. Swiss drugmakers In July, Trump sent letters to leaders of 17 major pharmaceutical companies, outlining how they should provide so-called most-favored-nation prices to the U.S. government's Medicaid health program for low-income people, and guarantee th ...

Group 1 - Multinational pharmaceutical companies are increasingly investing in the U.S., with GlaxoSmithKline (GSK) committing to invest $30 billion over the next five years, viewing the U.S. as its top priority market [3][4] - Other pharmaceutical companies have also announced significant investments in the U.S., including Eli Lilly's $27 billion, Johnson & Johnson's $55 billion, and Merck's $9 billion plans [3][4][5] - The U.S. pharmaceutical industry heavily relies on overseas supply chains for active pharmaceutical ingredients (APIs) and generic drugs, raising concerns about the feasibility of reshoring production [4][6] Group 2 - The U.K. pharmaceutical industry faces significant investment loss risks due to ongoing disputes over drug pricing controls, with the new VPAG scheme requiring companies to return 23.5% to 35.6% of brand drug revenues to the NHS [7][8] - The British pharmaceutical industry association has warned that maintaining high rebate rates could lead to a loss of approximately £11 billion in R&D investment by 2033 [7][8] - Recent actions by multinational companies, such as Merck canceling a £1 billion research hub in London and AstraZeneca pausing expansion plans, highlight the impact of the U.K. government's slow progress on life sciences investment [8]